Antidepressant escitalopram more effective at preventing relapse, analysis finds

Antidepressant escitalopram more effective at preventing relapse, analysis finds

Three pills came top and outperformed Prozac for preventing relapse in a large number of patients.

One drug comes out top in a large analysis, external of how effective antidepressants are at keeping patients free of symptoms of depression.

Escitalopram performed best at preventing patients from relapsing in a study involving nearly 10,000 people prescribed different medications for up to a year.

Two other pills - agomelatine and duloxetine - came next, while prozac (also known as fluoxetine) ranked just below them.

Experts stress the findings don't mean that everyone with severe depression should switch to escitalopram, or that other antidepressants aren't any good, because all the drugs can work and each has its pros and cons.

Depression is common, affecting around one in six people in the UK. With the right treatment and support, people can make a good recovery although for some their depression can return.

To prevent relapse, doctors already recommend people stay on antidepressants for at least six months after depression ends, and then taper off gradually.

The new analysis, published in The Lancet Psychiatry, looked at previous studies comparing the effectiveness of more than a dozen common antidepressants in total.

The differences found were modest and experts say longer studies are still needed to find out more.

There are many contributing causes to depression and a variety of ways to treat it, including drugs and talking therapies.

In brief

One drug comes out top in a large analysis, external of how effective antidepressants are at keeping patients free of symptoms of depression. Depression is common, affecting around one in six people in the UK. To prevent relapse, doctors already recommend people stay on antidepressants for at least six months after depression ends, and then taper off gradually.

This is the opening of the story, shared with credit to BBC News — Top Stories. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at BBC News — Top Stories ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.